- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Neoadjuvant Immunotherapy Promising in CRC, but Long-term Data Needed, Says Dr Kristen Ciombor
Kristen K Ciombor, MD, MSCI, associate professor at Vanderbilt University, explains that results of neoadjuvant immunotherapy in colorectal cancer are promising, but long-term data is still needed.
While not yet standard of care, neoadjuvant immunotherapy is showing positive responses in patients with colorectal cancer when using this type of experiemental approach, said Kirsten K. Ciombor, MD, MSCI, associate professor of medicine at Vanderbilt University, speaking at an Institute for Value-Based Medicine® meeting.
Transcript
What long-term survival data are you waiting to see in the use of neoadjuvant immunotherapy in colorectal cancer?
Neoadjuvant immunotherapy, it's still an experimental approach; it's not yet standard of care. But we're starting to see some really incredible responses, both in rectal cancer and colon cancer. We need to make sure that these responses, these tumor shrinkage data are really reliable, that they are reproducible, that they are generalizable to patients across the spectrum, and then of course, that they're durable.
We are hopeful that these early responses will translate to increased rates of cure, but we need more follow up data to ensure that's true.
Frameworks for Advancing Health Equity: Youth Behavioral Health Strategy Program
September 17th 2024Chris Barton, LCSW, of Horizon Blue Cross Blue Shield of New Jersey, explores how the Youth Behavioral Health Strategy program focuses on addressing the specific needs of youth with mental health and substance use issues through a comprehensive approach.
Listen
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Flatiron Health, Exact Sciences Announce Deal to Speed Evidence Generation With MRD Test
February 6th 2025The companies announced the deal in a statement February 5, 2025, noting that the first patient had enrolled in a prospective clinical study using the test to monitor cancer recurrence across multiple solid tumor types.
Read More
On World Cancer Day, NCCN Patient Advocates Share What Makes Their Journeys Unique
February 4th 2025World Cancer Day also marks the start of the ‘United by Unique’ campaign, which seeks to highlight how each person’s journey with cancer is unique, even though the patients, caregivers, and health care teams who are touched by cancer are united by shared goals.
Read More
